Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 415 of the 415 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
Background2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (1).”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534 · cited 2×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 2×
“Recent guidelines address bonespecific therapies (43).”
BackgroundWriting Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cited by
Items 101–200 of 883
Management of Primary Ovarian Insufficiency Symptoms in Survivors of Childhood and Adolescent Cancer
Gargus, E. S., Deans, R., Anazodo, A. C., & Woodruff, T. K. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7023 · Cited by 72
Cintrón-López, D., Lahr, B. D., Bailey, K. R., Santoro, N. F., Lloyd, R. M., Manson, J. E., Neal-Perry, G. S., Pal, L., Taylor, H. S., Wharton, W., et al. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000971 · Cited by 70
Female reproductive health in cystic fibrosis
Hughan, K. S., Daley, T. C., Rayas, M. S., Kelly, A. T., & Roe, A. H. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.024 · Cited by 78
Alexandraki, K., & Grossman, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122153 · Cited by 62
“Subcutaneous implants inserted on a 6-month basis may show tachyphylaxis and are difficult to reverse [11].”
BackgroundDiabetes in Menopause: Risks and Management
Paschou, S. Α., Anagnostis, P. G., Pavlou, D. I., Vryonidou, A., Goulis, D. G., & Lambrinoudaki, I. V. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180625124405 · Cited by 66
The many menopauses: searching the cognitive research literature for menopause types
Edwards, H., Duchesne, A., Au, A., & Einstein, G. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001171 · Cited by 84
“The clinical recommendations in these guidelines cover therapies for the most common symptoms of spontaneous menopause and, to an extent, spontaneous or induced early menopause.(3,6) The Endocrine Society cautions against using typical symptom management techniques for women with either premature or induced menopause,…”
InfluentialSanten, R. J., & Simpson, E. R. (2018) · Endocrinology · doi:10.1210/en.2018-00529 · Cited by 74
Self-citationLan, Y., Huang, Y., Song, Y., Ma, L., Chen, P., Ying, Q., Li, W., Cai, Y., & Zhou, J. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000906 · Cited by 70
A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause
Madsen, T. E., Sobel, T., Negash, S., Shrout, T. A., Stefanick, M. L., Manson, J. E., & Allison, M. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s379808 · Cited by 89
“Guidelines from several medical societies endorse treatment with MHT for women with premature or induced menopause, unless contraindicated, with the recommendation to continue treatment until at least the median population-based age of menopause.(2,3,20)”
BackgroundNeong, S. F., Billington, E. O., & Congly, S. E. (2019) · Hepatology · doi:10.1002/hep.30359 · Cited by 67
“The same contraindications and precautions considered in the general population should still be applied to patients with cirrhosis.(68) Nonhormonal therapies for managing the vasomotor symptoms play an important role in managing female SD.”
BackgroundThe other side of progestins: effects in the brain
Giatti, S., Melcangi, R. C., & Pesaresi, M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0061 · Cited by 58
“Data from Liu et al. (2010) and Stuenkel et al. (2015).”
Comeglio, P., Cellai, I., Filippi, S., Corno, C., Corcetto, F., Morelli, A., Maneschi, E., Maseroli, E., Mannucci, E., Fambrini, M., et al. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.10.007 · Cited by 64
“Compelling evidence indicates that administration of vaginal estrogens is an effective intervention for menopausal-related vaginal dryness and atrophy.(14) In addition to estrogens, testosterone (T) can modulate the female genital sexual arousal response.”
BackgroundThe Changing Clinical Spectrum of Hypophysitis
Chiloiro, S., Capoluongo, E., Tartaglione, T., Giampietro, A., Bianchi, A., Giustina, A., Pontecorvi, A., & Marinis, L. D. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.06.004 · Cited by 58
Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Chlebowski, R. T., Howard, B. V., Thomson, C. A., Margolis, K. L., et al. (2018) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000527868.87744.14 · Cited by 55
Pharmacotherapy for the treatment of vaginal atrophy
Donders, G. G. G., Ruban, K., Bellen, G., & Grincevičienė, Š. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574752 · Cited by 67
Menopause, hormone therapy and diabetes
Stuenkel, C. A. (2017) · Climacteric · doi:10.1080/13697137.2016.1267723 · Cited by 63
Self-citationUpdate on Menopausal Hormone Therapy for Fracture Prevention
Stepan, J. J., Hruskova, H., & Kverka, M. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00549-3 · Cited by 65
Australian women’s understanding of menopause and its consequences: a qualitative study
Herbert, D., Bell, R. J., Young, K., Brown, H. L., Coles, J. Y., & Davis, S. R. (2020) · Climacteric · doi:10.1080/13697137.2020.1791072 · Cited by 61
Self-citationIntharuksa, A., Arunotayanun, W., Takuathung, M. N., Chaichit, S., Prasansuklab, A., Chaikhong, K., Sirichanchuen, B., Chupradit, S., & Koonrungsesomboon, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146973 · Cited by 72
Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update
Paschou, S. Α., & Παπάνας, Ν. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00695-y · Cited by 67
The Impact of Estrogen Deficiency on Liver Metabolism: Implications for Hormone Replacement Therapy
Dong, J., Dennis, K. M. J. H., Venkatakrishnan, R., Hodson, L., & Tomlinson, J. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf018 · Cited by 72
Hypogonadism in thalassemia major patients
Srisukh, S., Ongphiphadhanakul, B., & Bunnag, P. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.001 · Cited by 52
“From the treatment of symptoms of the menopause clinical practice guideline of the Endocrine Society, randomized controlled trials (RCT) demonstrated that oral estrogen increases venous thromboembolism (VTE) risk in women aged 50 to 59 [40].”
MethodCusimano, M. C., Chiu, M., Ferguson, S. E., Moineddin, R., Aktar, S., Liu, N., & Baxter, N. N. (2021) · BMJ · doi:10.1136/bmj-2021-067528 · Cited by 65
Mehta, J. M., Chester, R. C., & Kling, J. M. (2018) · Journal of Women s Health · doi:10.1089/jwh.2018.7201 · Cited by 60
“2,6,16,17 Decreased medical school and residency training in menopause management has left many primary care providers unequipped to treat menopausal symptoms.”
Progesterone for treatment of symptomatic menopausal women
Prior, J. C. (2018) · Climacteric · doi:10.1080/13697137.2018.1472567 · Cited by 54
Managing menopausal symptoms after cancer
Szabo, R. A., Marino, J. L., & Hickey, M. (2019) · Climacteric · doi:10.1080/13697137.2019.1646718 · Cited by 48
Coronary Microvascular Dysfunction and Estrogen Receptor Signaling
Tunc, E. P., Eve, A. A., & Madak‐Erdogan, Z. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.11.001 · Cited by 49
Shepherd‐Banigan, M. E., Goldstein, K. M., Coeytaux, R. R., McDuffie, J. R., Goode, A. P., Kosinski, A. S., Noord, M. V., Befus, D., Adam, S. S., Masilamani, V., et al. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.08.011 · Cited by 51
Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors
Quick, A. M., Zvinovski, F., Hudson, C. O., Hundley, A. F., Evans, C. D., Suresh, A., Stephens, J. A., Arthur, E. K., Ramaswamy, B., Reinbolt, R. E., et al. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-05211-3 · Cited by 45
“The use of vaginal estrogens to treat GSM is the gold standard treatment for GSM in postmenopausal women without a history of breast cancer [30] but is controversial in breast cancer survivors, due to concern for increase cancer recurrence risk [7].”
BackgroundExogenous hormones and hereditary angioedema
Gompel, A., Fain, O., Boccon‐Gibod, I., Gobert, D., & Bouillet, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106080 · Cited by 49
Self-citationEstrogen and bones after menopause: a reappraisal of data and future perspectives
Anagnostis, P. G., Bosdou, J. Κ., Vaitsi, K., Goulis, D. G., & Lambrinoudaki, I. V. (2020) · HORMONES · doi:10.1007/s42000-020-00218-6 · Cited by 55
Menopausal Hormone Therapy: a Comprehensive Review
Lundberg, G. P., Wu, P., & WENGER, N. K. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00854-8 · Cited by 49
Quick, A. M., Dockter, T., Le‐Rademacher, J. G., Salani, R., Hudson, C. O., Hundley, A. F., Terstriep, S. A., Streicher, L. F., Faubion, S. S., Loprinzi, C. L., et al. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.10.018 · Cited by 51
Effect of menopausal hormone therapy on components of the metabolic syndrome
Lovre, D., Lindsey, S. H., & Mauvais-Jarvis, F. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716649358 · Cited by 44
“Further, recent Endocrine Society clinical practice guidelines do recommend caution regarding the use of MHT in patients with MetS [Stuenkel et al. 2015] as it is associated with higher risks of cardiovascular events [Esposito et al.”
BackgroundSafety and benefit considerations for menopausal hormone therapy
Pickar, J. H., Archer, D. F., Kagan, R., Pinkerton, J. V., & Taylor, H. S. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1343298 · Cited by 51
“Surveys of US women estimate that CBHT accounts for 28% to 68% of all HT prescriptions [72,73], amounting to $1 to $2 billion dollars per year [72].”
BackgroundInfluentialSelf-citationKnowledge and attitudes of health professionals regarding menopausal hormone therapies
Yeganeh, L., Boyle, J. A., Teede, H. J., & Vincent, A. J. (2017) · Climacteric · doi:10.1080/13697137.2017.1304906 · Cited by 48
The Influence of Menopause in Multiple Sclerosis Course: A Longitudinal Cohort Study
Ladeira, F. F., Salavisa, M., Caetano, A., Barbosa, R. P., Sá, F., & Correia, A. S. (2018) · European Neurology · doi:10.1159/000496374 · Cited by 43
Appleton, S., Gill, T., Taylor, A., McEvoy, D., Shi, Z., Hill, C., Reynolds, A., & Adams, R. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15050930 · Cited by 42
“HRT was used in only 5% of women in our study, of whom 60% were aged under 60 years, which is the age group showing a more favorable HRT-related risk profile for CVD and mortality [35,36].”
MethodRossouw, J. E., Aragaki, A. K., Manson, J. E., Szmuilowicz, E. D., Harrington, L. B., Johnson, K., Allison, M., Haring, B., Saquib, N., Shadyab, A. H., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.4510 · Cited by 48
Reproductive Health as a Marker of Subsequent Cardiovascular Disease: The Role of Estrogen
Manson, J. E., & Woodruff, T. K. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2662 · Cited by 43
Martins, S. C., Araújo, M. A. M., de Moura, J. P. M., Costa, A. C. M., Martins, J. S. R., & Pinheiro, M. B. S. T. (2021) · Revista Médica de Minas Gerais · doi:10.5935/2238-3182.20210036 · Cited by 40
Menown, S. J., & Tello, J. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01900-w · Cited by 45
Examining the Health-Related Needs of Females during Menopause: A Systematic Review Study
Rostami-Moez, M., Masoumi, S. Z., Otogara, M., Farahani, F., Alimohammadi, S., & Oshvandi, K. (2023) · Journal of Menopausal Medicine · doi:10.6118/jmm.22033 · Cited by 56
“(2015) [25] Clinical trial; Cross-sectional; Cohort; Cohort; Systematic review; Narrative review; Review; Meta-analysis 1) The data show a high prevalence of osteoporosis from the age of 65 onwards.”
BackgroundInfluentialLu, J., Li, K., Zheng, X., Liu, R., Chen, M., Xian, J., Tu, S., & Xie, L. (2023) · BMC Women s Health · doi:10.1186/s12905-023-02621-8 · Cited by 52
“It is clearly stated in the Endocrine Society Clinical Practice Guidelines [16] that MHT needs to be individualized according to a standardized diagnosis and treatment process, and women receiving MHT should receive corresponding health guidance to develop better management strategies.”
BackgroundMorga, A., Ajmera, M., Gao, E., Patterson‐Lomba, O., Zhao, A., Mancuso, S., Siddiqui, E. J., & Kagan, R. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002281 · Cited by 47
Ovariectomy Alters Gene Expression of the Hippocampal Formation in Middle-Aged Rats
Sárvári, M., Kalló, I., Hrabovszky, E., Solymosi, N., & Liposits, Z. (2016) · Endocrinology · doi:10.1210/en.2016-1516 · Cited by 42
Menopausal Symptoms and Associated Social and Environmental Factors in Midlife Chinese Women
Zhang, L., Ruan, X., Cui, Y., Gu, M., & Mueck, A. O. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s278976 · Cited by 48
The Effects of Environmental Contaminant Exposure on Reproductive Aging and the Menopause Transition
Neff, A. M., Laws, M. J., Warner, G. R., & Flaws, J. A. (2022) · Current Environmental Health Reports · doi:10.1007/s40572-022-00334-y · Cited by 45
Menopausal hormone therapy in cancer survivors: A narrative review of the literature
Kuhle, C. L., Kapoor, E., Sood, R., Thielen, J. M., Jatoi, A., & Faubion, S. S. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.07.018 · Cited by 45
Menopausal hormone therapy in women with medical conditions
Kapoor, E., Kling, J. M., Lobo, A. S., & Faubion, S. S. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101578 · Cited by 49
Blanken, A. E., Gibson, C. J., Li, Y., Huang, A. J., Byers, A. L., Maguen, S., Inslicht, S. S., & Seal, K. H. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001978 · Cited by 38
“models were adjusted a priori for age, body mass index (BMI), and depression due to known influence on menopause symptomology and experience.(20) Models with hormone therapy as the outcome were also adjusted for the presence of menopause symptoms.”
MethodLialy, H. E., Mohamed, M. A., AbdAllatif, L. A., Khalid, M., & Elhelbawy, A. (2023) · BMC Women s Health · doi:10.1186/s12905-023-02515-9 · Cited by 43
“It increases hormones levels such as serotonin and the serum concentration of the brain-derived neurotrophic factor, thus, reducing depression and improving sleep without any change in oxidative stress [8, 9].”
BackgroundA systematic review and critical appraisal of menopause guidelines
Hemachandra, C., Taylor, S., Islam, R. M., Fooladi, E., & Davis, S. R. (2024) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2023-202099 · Cited by 45
Self-citationSchaudig, K., Wang, X., Bouchard, C., Hirschberg, A. L., Cano, A., M, M. S. C., Stute, P., Wu, X., Miyazaki, K., Scrine, L., et al. (2024) · BMJ · doi:10.1136/bmj-2024-079525 · Cited by 45
A model of care for healthy menopause and ageing: EMAS position statement
Stute, P., Ceauşu, I., Depypere, H. T., Lambrinoudaki, I. V., Mueck, A. O., Pérez-López, F. R., van der Schouw, Y. T., Senturk, L. M., Simoncini, T., Stevenson, J. C., et al. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.06.018 · Cited by 38
Torres, M. J., RYAN, T. E., Lin, C., Zeczycki, T. N., & Neufer, P. D. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005148 · Cited by 44
“In fact, ET is normally contraindicated in women with active liver disease or a history of liver disease (7, 27).”
BackgroundCardiometabolic Effects of Endocrine Treatment of Estrogen Receptor–Positive Early Breast Cancer
Cheung, Y.-M. M., Ramchand, S. K., Yeo, B. J., & Grossmann, M. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00096 · Cited by 41
“These effects are complex and depend on age, comorbidities, genetic background, and, with respect to exogenous estrogens, on dose, route (oral vs transdermal), and timing (early vs late menopause) of administration, and on concomitant progestin treatment [5].”
BackgroundGabapentin for the treatment of hot flushes in menopause: a meta-analysis
Yoon, S.-H., Lee, J. Y., Lee, C., Lee, H., & Kim, S.-N. (2020) · Menopause · doi:10.1097/gme.0000000000001491 · Cited by 35
“attack, or stroke; unexplained vaginal bleeding; high-risk endometrial cancer; and active liver disease.(8)”
BackgroundVaginal Health During Breast Cancer Treatment
Falk, S. J., & Bober, S. L. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0517-x · Cited by 35
The sex life of women surviving breast cancer
Ghizzani, A., Bruni, S., & Luisi, S. V. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1467401 · Cited by 35
“No data are available on concomitant use with medical treatment of premature or advanced breast cancer and they should be used for vaginal atrophy only after both breast cancer treatment and adjuvant therapy are completed [31].”
BackgroundUnderlying Breast Cancer Risk and Menopausal Hormone Therapy
Santen, R. J., Heitjan, D. F., Gompel, A., Lumsden, M. A., Pinkerton, J. V., Davis, S. R., & Stuenkel, C. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa073 · Cited by 38
Self-citationHypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Pettigrew, J., & Novick, A. M. (2021) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13283 · Cited by 46
Stute, P., Cano, A., Thurston, R. C., Small, M., Lee, L., Scott, M., Siddiqui, E. J., & Schultz, N. M. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.06.008 · Cited by 37
Gürler, M., Kızılırmak, A., & Başer, M. (2020) · Complementary Medicine Research · doi:10.1159/000507751 · Cited by 40
Sulaica, E. M., Han, T., Wang, W., Bhat, R. R., Trivedi, M. V., & Niravath, P. A. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3827-7 · Cited by 31
Miller, V. M., Kling, J. M., Files, J. A., Joyner, M. J., Kapoor, E., Moyer, A. M., Rocca, W. A., & Faubion, S. S. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001065 · Cited by 37
Løbo, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00014-7 · Cited by 43
Management of Menopause Symptoms and Quality of Life during the Menopause Transition
Ye, L., Knox, B., & Hickey, M. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.04.006 · Cited by 43
Migraine, hormones and the menopausal transition
Rodrigues, M. A. H., Maitrot‐Mantelet, L., Plu‐Bureau, G., & Gompel, A. (2018) · Climacteric · doi:10.1080/13697137.2018.1439914 · Cited by 41
Self-citationMicronized progesterone, progestins, and menopause hormone therapy
Rodrigues, M. A. H., & Gompel, A. (2020) · Women & Health · doi:10.1080/03630242.2020.1824956 · Cited by 34
Self-citationProgestogens as a component of menopausal hormone therapy: the right molecule makes the difference
Stevenson, J. C., Rozenberg, S., Maffei, S., Egarter, C., Stute, P., & Römer, T. (2020) · Drugs in Context · doi:10.7573/dic.2020-10-1 · Cited by 37
Tseng, P., Chiu, H., Suen, M., Zeng, B., Wu, M., Tu, Y., Hung, K., Wu, Y., Su, K., Li, D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115316 · Cited by 34
Experiences of menopause among non-binary and trans people
Toze, M., & Westwood, S. (2024) · International Journal of Transgender Health · doi:10.1080/26895269.2024.2389924 · Cited by 37
“Clinically, menopause is defined in relation to the date of the final menstrual period, and consequent cessation of ovarian function (Stuenkel et al., 2015).”
Vaginal estradiol use and the risk for cardiovascular mortality
Mikkola, T. S., Tuomikoski, P., Lyytinen, H. K., Korhonen, P. A., Hoti, F. J., Vattulainen, P., Gissler, M., & Ylikorkala, O. (2016) · Human Reproduction · doi:10.1093/humrep/dew014 · Cited by 32
Gittens, P. R., & Mullen, G. (2018) · Journal of Cosmetic and Laser Therapy · doi:10.1080/14764172.2018.1481510 · Cited by 33
“Several first-line therapies treating GSM are currently recommended by the North American Menopause Society and The Endocrine Society including vaginal moisturizers, continued sexual activity, and lubricants (6,7).”
BackgroundAntidepressants during and after Menopausal Transition: A Systematic Review and Meta-Analysis
Wu, C.-K., Tseng, P., Wu, M., Li, D., Chen, T., Kuo, F., Stubbs, B., Carvalho, A. F., Chen, Y., Lin, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64910-8 · Cited by 34
Rodríguez‐Rodríguez, I., Rodríguez, J., & Zamora, M. Á. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4826984 · Cited by 31
“Continuing with special situations in the life of diabetic women, it is necessary to pay attention to menstruation, menopause [68], or the progression of osteoporosis [69].”
BackgroundLiu, J., Jin, X., Chen, W., Wang, L., Feng, Z., & Huang, J. (2023) · Maturitas · doi:10.1016/j.maturitas.2023.107784 · Cited by 36
The role of local estrogen therapy in the management of pelvic floor disorders
Tzur, T., Yohai, D., & Weintraub, A. Y. (2016) · Climacteric · doi:10.3109/13697137.2015.1132199 · Cited by 33
Current Obstetrics and Gynecology Reports
(2013) · Current Obstetrics and Gynecology Reports · doi:10.1007/13669.2161-3303 · Cited by 29
Parish, S. J., Nappi, R. E., & Kingsberg, S. A. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001088 · Cited by 31
Towards optimization of estrogen receptor modulation in medicine
Valera, M., Fontaine, C., Dupuis, M., Noirrit‐Esclassan, E., Vinel, A., Guillaume, M., Gourdy, P., Lenfant, F., & Arnal, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.002 · Cited by 29
Antônio, F. I., Herbert, R., Bø, K., Silva, A. C. J. D. S. R. E., Lara, L. A. D. S., Franco, M. D. M., & Ferreira, C. H. J. (2018) · Journal of physiotherapy · doi:10.1016/j.jphys.2018.05.002 · Cited by 38
Menopause guideline appraisal and algorithm development for premature ovarian insufficiency
Yeganeh, L., Boyle, J. A., Wood, A. J., Teede, H. J., & Vincent, A. J. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.09.009 · Cited by 30
Serum estradiol level according to dose and formulation of oral estrogens in postmenopausal women
Kim, S.-M., Kim, S. E., Lee, D., & Choi, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-81201-y · Cited by 28
Milner, T. A., Contoreggi, N. H., Yu, F., Johnson, M. A., Wang, G., Woods, C., Mazid, S., Kempen, T. A. V., Waters, E. M., McEwen, B. S., et al. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0164-21.2021 · Cited by 36
Hypertension Across a Woman’s Life Cycle
Ghazi, L., Annabathula, R. V., Bello, N. A., Zhou, L., Stacey, R. B., & Upadhya, B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01230-4 · Cited by 40
Prior, J. C., Cameron, A., Fung, M., Hitchcock, C. L., Janssen, P. A., Lee, T., & Singer, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-35826-w · Cited by 32
Correlations between sex-related hormones, alcohol dependence and alcohol craving
Ho, A. M., Geske, J. R., Bakalkin, G. Y., Winham, S. J., & Karpyak, V. M. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.029 · Cited by 29
Review of Hormone Replacement Therapy in Girls and Adolescents with Hypogonadism
Klein, K. O., & Phillips, S. A. (2019) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2019.04.010 · Cited by 29
Endothelial dysfunction and menopause: is exercise an effective countermeasure?
Witkowski, S., & Serviente, C. F. (2018) · Climacteric · doi:10.1080/13697137.2018.1441822 · Cited by 34
An Update on Menopause Management
Ward, K., & Deneris, A. (2018) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.12737 · Cited by 29
Reproductive Care of Childhood and Adolescent Cancer Survivors: A 12-Year Evaluation
Anazodo, A. C., Choi, S., Signorelli, C., Ellis, S. J., Johnston, K. A., Wakefield, C. E., Deans, R., Neville, K. A., & Cohn, R. J. (2020) · Journal of Adolescent and Young Adult Oncology · doi:10.1089/jayao.2020.0157 · Cited by 30
Sex hormones, vascular factors and cognition
Szoeke, C. E. I., Downie, S., Parker, A. F., & Phillips, S. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100927 · Cited by 27
Mahbub, A. A., Aslam, A., Elzubier, M., El‐Boshy, M., Abdelghany, A. H., Ahmad, J., Idris, S., Almaimani, R. A., Alsaegh, A., El-Readi, M. Z., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.941834 · Cited by 35
“7 μg/kg/day) recommended for postmenopausal women of 60 kg body weight (32).”
BackgroundHormone replacement therapy in women with history of thrombosis or a thrombophilia
Morris, G., & Talaulikar, V. S. (2022) · Post Reproductive Health · doi:10.1177/20533691221148036 · Cited by 34
“A history of VTE due to pregnancy, oral contraceptives, unknown aetiology or blood clotting disorders poses a contraindication to any estrogen therapy, whereas VTE due to past immobility, surgery, or bone fracture would be a contraindication to oral but not necessarily transdermal MHT’.34 The British Menopause Society…”
BackgroundThe Effect of Vitamin E Supplementation in Postmenopausal Women—A Systematic Review
Feduniw, S., Korczyńska, L., Górski, K., Zgliczyńska, M., Bączkowska, M., Byrczak, M., Kociuba, J., Ali, M. K., & Ciebiera, M. (2022) · Nutrients · doi:10.3390/nu15010160 · Cited by 32
“According to available data, hormone therapy is the most effective treatment in this indication [7,8].”
MethodKiriakova, V., Cooray, S. D., Yeganeh, L., Somarajah, G., Milat, F., & Vincent, A. J. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.07.021 · Cited by 30
Evaluation and Management of Primary Ovarian Insufficiency in Adolescents and Young Adults
Kanj, R. V., Ofei-Tenkorang, N. A., Altaye, M., & Gordon, C. M. (2017) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2017.07.005 · Cited by 29
Williams, J. A. E., Chester‐Jones, M., Lowe, C., Goff, M., Francis, A., Brewer, G., Marian, I. R., Morris, S. L., Warwick, D., Eldridge, L., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00218-1 · Cited by 30
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.